Legislature(2021 - 2022)DAVIS 106
03/30/2021 03:00 PM House HEALTH & SOCIAL SERVICES
Note: the audio
and video
recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
| Audio | Topic |
|---|---|
| Start | |
| SB70 | |
| HB119 | |
| SB70 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| + | SB 70 | TELECONFERENCED | |
| *+ | HB 119 | TELECONFERENCED | |
SB 70-OPIOID OVERDOSE DRUGS
3:06:20 PM
CO-CHAIR SNYDER announced that the first order of business would
be CS FOR SENATE BILL NO. 70(HSS), "An Act relating to opioid
overdose drugs; and providing for an effective date."
3:07:01 PM
SENATOR DAVID WILSON, Alaska State Legislature, as prime
sponsor, presented CSSB 70(HSS). He explained that CSSB 70(HSS)
allows the state medical officer to continue to issue a
statewide standing order for the opioid overdose reversal drug
Naloxone, also called Narcan. He explained this is to remove a
four-year sunset clause on a previous bill from 2017. By
removing the sunset date, local and regional response programs,
first responders, the Department of Public Safety (DPS), the
Department of Corrections (DOC), and the public will continue to
have the ability to directly distribute and have access to the
life saving drug, Naloxone, he stated.
SENATOR WILSON said Naloxone is not a controlled substance and
has no potential for abuse. He stated that CSSB 70(HSS) would
benefit the many friends and family of the people who would die
of overdose without this life-saving medication.
3:09:21 PM
JASMIN MARTIN, Staff, Senator David Wilson, Alaska State
Legislature, presented the sectional summary of CSSB 70(HSS)
which read as follows [original punctuation provided]:
Section 1: Repeals language regarding the sunset of
the original authorization.
Section 2: Changes the reporting requirement to
reference opioid overdose drugs distribution.
Section 3: Repeals the sunset date of the original
standing order authorization.
Section 4: Immediate effective date.
SENATOR WILSON commented that the Department of Health and
Social Services (DHSS) had a presentation for the committee.
3:10:40 PM
REPRESENTATIVE PRAX asked if there was an expense associated
with the annual report from Section 2, and if the report was
necessary and added value.
SENATOR WILSON answered yes, and that in the original Senate
Bill 91 from the Thirtieth Alaska State Legislature, there was a
reporting mechanism. He explained that there was an attempt to
remove the requirement, but the Senate Health and Social
Services Standing Committee felt that the report was useful.
3:12:03 PM
CO-CHAIR SNYDER observed that the language changed components of
the report, so now it referenced the various Substance Abuse and
Mental Health Services Administration (SAMHSA) grants, and
specifically opioid overdose drug distribution. She asked if
there were any particular metrics that might be lost with that
wording change.
SENATOR WILSON said that question had been asked previously, and
it was his understanding that the same items would be measured.
He said the difference was because of language associated with
the emergency declaration.
3:13:19 PM
REPRESENTATIVE MCCARTY said he thought this was put into place
before COVID-19 and asked if the term "opioid epidemic" was a
SAMHSA classification for grant purposes.
SENATOR WILSON answered that in 2017 Governor Bill Walker
introduced an emergency declaration on the opioid epidemic in
Alaska. He said it was all SAMHSA funding.
3:14:39 PM
REPRESENTATIVE SPOHNHOLZ commented that at the time that the
legislature passed Senate Bill 91, there were still rising case
counts as related to opioid overdoses, the country was in the
middle of a national opioid epidemic, and that is why that
language was utilized. She explained that there has been
progress with the opioid epidemic and therefore the language is
no longer used the same way. She said it was learned that
having Naloxone available saves lives.
REPRESENTATIVE MCCARTY stated that the sunset is based on the
standing order. He asked if the chief medical officer could
decide to change the standing order "without worrying about
legislative action."
SENATOR WILSON answered yes. He explained the idea of the
sunset was because that is when the funds ended federally for
the program. Because this was a successful program and there
was a continuation of the federal funding, his office felt it
was a good practice [and sought to continue the program]. He
also shared that if a better drug or treatment were to become
available, the Chief Medical Officer could update the protocol
if needed.
3:16:59 PM
CO-CHAIR SNYDER introduced a presentation from DHSS.
3:18:28 PM
THERESE WELTON, Chief, Office of Substance Misuse and Addiction
Prevention, Division of Public Health, Department of Health and
Social Services, presented a PowerPoint, entitled "SB 70 Opioid
Overdose Drugs" [hard copy included in the committee packet].
MS. WELTON introduced slide 2, which outlined the steps of an
overdose, which she said takes only minutes to happen. She
explained that if Naloxone is not immediately available, it may
take over 20 minutes for Emergency Medical Services (EMS) to
arrive, which may be too late. She moved slide to 3, which
showed a graph of the increase in opioid deaths since 1999.
3:19:50 PM
MS. WELTON moved to slide 4 and stated that "too many Alaskans
have lost their lives to overdose" even though it is preventable
with the administration of Naloxone. She shared that overdoses
were one of the top ten leading causes of death in 2017.
3:20:18 PM
The committee took a brief at-ease at 3:20 p.m.
[Due to technical difficulties, the audio following the at-ease
is not available Information from slides 5-7 has been provided
from the secretary's log notes and committee packet documents.]
MS. WELTON said overdose can cause significant medical impact on
a person when that person does not receive timely administration
of Naloxone. She emphasized that it takes just three minutes
for a person who overdosed to experience brain damage, and eight
minutes to die. She shared that it only takes three to four
minutes for paramedics to arrive on scene in Anchorage, but in
rural areas it can take much longer for first responders to
arrive on the scene. She said that people who survive overdose
with brain injury can have [many long-term complications].
MS. WELTON presented slide 5 and informed the committee members
that in the U.S. and Alaska synthetic opioids appear to be the
primary driver of the increases in overdose deaths, increasing
38.4 percent from the 12-month period leading up to June 2019,
compared with the 12-month period leading up to May 2020.
MS. WELTON presented slide 6 and said the World Health
Organization (WHO), the U.S. Surgeon General, and the U.S.
Society of Addiction Medicine have recommended that Naloxone is
accessible to those closest to a person using opiates.
MS. WELTON presented slide 7 and explained that the current
standing order allows Naloxone to be dispensed to any
individuals who are not prescribers, which is generally
prohibited. She stressed that Naloxone is not a controlled
substance, has no potential for abuse and is safe to use. She
argued that by removing the sunset date, local and regional
response programs, first responders, DPS and DOC, and the
general public will continue to be able to use Naloxone.
3:23:54 PM
MS. WELTON presented slide 8 and shared that all Naloxone
distributed to community partners is 100 percent federally
funded by the SAMHSA grant program. She shared this was used to
form Project HOPE, which stands for Harm reduction, Opioid
Prevention, and Education, which works to distribute and
administer Narcan [the brand name for Naloxone] in Alaska with
127 community partners. Thus far Project HOPE has been part of
309 documented overdose-reversals, she shared.
MS. WELTON presented slide 9 and said that administration of
Naloxone provides opportunity for recovery, and she argued that
saving lives saves costs. She said that 40 percent of the
economic burden of the opioid crisis is driven by lost lifetime
earnings; 33 percent is by excess healthcare spending; 15
percent is from lost productivity in the work force, and 6
percent is from criminal justice costs.
MS. WELTON presented slide 10 and said the current standing
medical order allows Naloxone to be dispensed to any individuals
who are not prescribers, which is generally prohibited for
medication. She reiterated that it is not a controlled
substance and has no potential for abuse and is safe to use.
She said that by removing the sunset date, [interested parties]
will be able to distribute and use the life-saving drug
Naloxone. She shared that the report in CSSB 70 (HSS) would
still provide information on the opiate epidemic and the opiate
overdose drug distribution.
MS. WELTON closed her presentation with slide 11. She said
without passage of CSSB 70(HSS) Naloxone would be available only
to those with a prescription from a medical provider submitted
to a pharmacy, which she argued makes the legislation
imperative.
3:26:54 PM
REPRESENTATIVE MCCARTY referenced slide 5. He observed the
increase from 2018 to 2019 in opioid death rates in Alaska and
asked if it was because of an increase in Fentanyl use.
MS. WELTON answered that that is the preliminary thought.
CO-CHAIR SNYDER commented that she wished to move the
legislation out of committee after public testimony.
3:28:47 PM
CO-CHAIR SNYDER opened public testimony on CSSB 70(HSS).
3:29:04 PM
VENUS WOODS, Director, HIV Prevention and Education, Alaska AIDS
Assistance Association ("Four A's"), testified in favor of CSSB
70(HSS). She said the legislation was important for Four A's
and shared that the organization runs Anchorage's only syringe
service program. She explained that the program provides
overdose education and gives out Narcan kits. She said without
SB 70, Four A's would no longer be able to give out the kits,
and she believed overdose deaths would increase.
3:30:30 PM
CO-CHAIR SNYDER closed public testimony.
REPRESENTATIVE SPOHNHOLZ commented that the program has been
very effective, and that it creates an opportunity anytime
somebody doesn't die from an overdose to find a path to
recovery. She said the program has become the standard nation-
wide. She said it was initially [set to sunset after] four-
years because it was a new thing that hadn't yet been done. She
emphasized the program has proven to be effective, very safe,
and is recommended by the U.S. Surgeon General, and therefore,
she believed it made sense to move CSHB 70(HSS) from committee.
[Discussion of CSSB 70(HSS) was concluded later in the meeting.]
SB 70-OPIOID OVERDOSE DRUGS
4:33:32 PM
CO-CHAIR SNYDER announced that the final order of business would
be a return to CS FOR SENATE BILL NO. 70(HSS), "An Act relating
to opioid overdose drugs; and providing for an effective date."
4:34:08 PM
CO-CHAIR ZULKOSKY moved to report CSSB 70(HSS) out of committee
with individual recommendations and the accompanying fiscal
notes. There being no objection, CSSB 70(HSS) was reported out
of the House Health and Social Services Standing Committee.
| Document Name | Date/Time | Subjects |
|---|---|---|
| (H)HSS, 3.29-4.2 Meeting Notice.pdf |
HHSS 3/30/2021 3:00:00 PM |
|
| SB 70 v. B.PDF |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| SB 70 Sponsor Statement 2.10.21.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 Summary of Changes v. A-B.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| SB 70 Sectional Summary v B.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| SB 70 Naloxone Standing Order Fact Sheet1-21-21.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 Opioid Leg Report DHSS 9.28.20.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 Opioid Leg Report DHSS 2017-18.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 FN DHSS.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 SLA 2017 SB 91.PDF |
HHSS 3/30/2021 3:00:00 PM SHSS 2/16/2021 1:30:00 PM |
SB 70 |
| SB 70 DHSS Invited Testimony - SHSS - 02162021.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| SB 70 DHSS Invited Testimony - SHSS - 02162021.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| SB 70 CS for SB 70 (HSS) v B.pdf |
HHSS 3/30/2021 3:00:00 PM SHSS 2/18/2021 1:30:00 PM |
SB 70 |
| SB 70 LOS 3.1.21.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| HB 119 Transmittal Letter.pdf |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB 119 Version 32 GH 1708 A.PDF |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB 119 Sectional Analysis Version GH 1708 A.pdf |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB0119-1-2-030121-DHS-Y.PDF |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB0119-3-2-030121-DHS-Y.PDF |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB0119-2-2-030121-DHS-Y.PDF |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| HB 119 Adult Foster Care for Disabled Graphic.pdf |
HHSS 3/30/2021 3:00:00 PM |
HB 119 |
| SB 70 DHSS Invited Testimony - HHSS- 03302021.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |
| ACEP SB70 Letter of Support.pdf |
HHSS 3/30/2021 3:00:00 PM |
SB 70 |